Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M.
作者信息
Zhang Xiaoying
机构信息
Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
出版信息
Glob Med Genet. 2021 Jun 26;8(4):133-134. doi: 10.1055/s-0041-1731067. eCollection 2021 Dec.
Abstract
摘要
相似文献
1
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M.
Glob Med Genet. 2021 Jun 26;8(4):133-134. doi: 10.1055/s-0041-1731067. eCollection 2021 Dec.
2
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.
3
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
J Thorac Oncol. 2017 Nov;12(11):1723-1727. doi: 10.1016/j.jtho.2017.06.017. Epub 2017 Jun 27.
4
Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Ann Transl Med. 2021 Jun;9(11):950. doi: 10.21037/atm-21-2823.
5
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Lung Cancer. 2020 Jan;139:133-139. doi: 10.1016/j.lungcan.2019.11.018. Epub 2019 Nov 24.
6
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Mol Oncol. 2017 Jun;11(6):670-681. doi: 10.1002/1878-0261.12063. Epub 2017 May 2.
7
Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
Mol Clin Oncol. 2019 Aug;11(2):127-131. doi: 10.3892/mco.2019.1880. Epub 2019 Jun 13.
8
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi: 10.1016/j.jtho.2020.04.014. Epub 2020 Apr 27.
9
Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
Mol Clin Oncol. 2017 Apr;6(4):525-528. doi: 10.3892/mco.2017.1181. Epub 2017 Mar 3.
10
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
Onco Targets Ther. 2017 Mar 22;10:1757-1766. doi: 10.2147/OTT.S100650. eCollection 2017.
本文引用的文献
1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758.
3
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer.
Clin Cancer Res. 2021 Feb 15;27(4):992-1002. doi: 10.1158/1078-0432.CCR-20-1690. Epub 2020 Oct 12.
4
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260.
5
Cancer burden of major cancers in China: A need for sustainable actions.
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
6
A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
Cancer Commun (Lond). 2019 Nov 1;39(1):67. doi: 10.1186/s40880-019-0413-5.
7
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
8
Pathological transition as the arising mechanism for drug resistance in lung cancer.
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
9
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
10
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
Zotero 插件